CD5 antibody | YKIX322.3
Filter by Application:F Reset
Rat anti Dog CD5:Alexa Fluor®488
- Product Type
- Monoclonal Antibody
|Rat anti Dog CD5 antibody, clone YKIX322.3 recognizes canine CD5, a 67 kDa cell surface type 1 transmembrane glycoprotein also known as lymphocyte antigen T1, Ly-1 or Leu-1. CD5 is expressed on the surface of T-cells and thymocytes, CD5 is also expressed by NK cells at low levels (Huang et al. 2008). Rat anti dog CD5, cloneYKIX322.3 was clustered as canine CD5 in the First Canine Leucocyte Antigen Workshop (Cobbold et al. 1994).
In a study of 73 cases of canine chronic lymphocytic leukemia (CLL) CD5 expression was absent on all cases of B-cell CLL as defined by CD21 expression and lack of CD3 or other T cell antigen expression (Vernau and Moore 1999). Rat anti dog CD5 serves as a useful marker for the discrimination of canine leukemias of differing origins (Deravi et al. 2017).
- Target Species
- Product Form
- Purified IgG conjugated to Alexa Fluor 488 - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% sodium azide (NaN3)
1% bovine serum albumin
- Concanavilin A activated canine peripheral blood cells
- Approx. Protein Concentrations
- IgG concentration 0.05mg/ml
- Fusion Partners
- Spleen cells from an immunised DA rat were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line
- Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm) Alexa Fluor®488 495 519
- For research purposes only
- 12 months from date of despatch
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or firstname.lastname@example.org
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
|Application Name||Verified||Min Dilution||Max Dilution|
- Flow Cytometry
- Use 10μl of the suggested working dilution to label 106 cells or 100μl of whole blood
|Description||Product Code||Applications||Pack Size||List Price||Your Price||Quantity|
|Rat IgG2a Negative Control:Alexa Fluor® 488||MCA1212A488||F||100 Tests/1ml||Log in|
|List Price||Your Price|
|Description||Rat IgG2a Negative Control:Alexa Fluor® 488|
|Rat IgG2a Negative Control:Alexa Fluor® 488||MCA6005A488||F||100 Tests/1ml||Log in|
|List Price||Your Price|
|Description||Rat IgG2a Negative Control:Alexa Fluor® 488|
References for CD5 antibody
Cobbold, S/ & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
Tissue Antigens. 43 (3): 137-54.
Hewicker-Trautwein, M. et al. (1999) Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease.
Vet Immunol Immunopathol. 67 (4): 341-57.
Vernau, W. & Moore, P.F. (1999) An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction.
Vet Immunol Immunopathol. 69: 145-64.
Guarga, J.L. et al. (2002) Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis.
Vet Immunol Immunopathol. 88: 13-20.
Burnett, R.C. et al. (2003) Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes.
Vet Pathol. 40: 32-41.
Lamerato-Kozicki, A.R. et al. (2006) Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation.
Exp Hematol. 34 (7): 870-8.
Fosmire, S.P. et al. (2007) Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.
Vet Pathol. 44: 467-78.
(2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells.
J Leukoc Biol. 84: 1501-10.
View The Latest Product References
Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
Vet Immunol Immunopathol. 141: 64-75.
GomesMde, O. et al. (2011) Old beagle dogs have lower faecal concentrations of some fermentation products and lower peripheral lymphocyte counts than young adult beagles.
Br J Nutr. 106 Suppl 1: S187-90.
Rütgen, B.C. et al. (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model.
PLoS One. 7 (6): e40078.
Michael, H.T. et al. (2013) Isolation and characterization of canine natural killer cells.
Vet Immunol Immunopathol. 155 (3): 211-7.
Aricò, A. et al. (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
BMC Vet Res. 9: 94.
Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
Vet Comp Oncol. 12: 29-36.
Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
Vet Immunol Immunopathol. 159 (1-2): 91-6.
Stokol, T. et al. (2015) Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog.
Vet Clin Pathol. 44 (1): 79-93.
Ito, D. et al. (2015) A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.
F1000Res. 4: 42.
Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
Immunobiology. 221 (1): 12-22.
Gibbons, N. et al. (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs.
Vet Immunol Immunopathol. 190: 26-30.
Deravi, N. et al. (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes.
Vet Immunol Immunopathol. 191: 5-13.
MariaA, P.J. et al. (2017) The effect of age and carbohydrate and protein sources on digestibility, fecal microbiota, fermentation products, fecal IgA, and immunological blood parameters in dogs.
J Anim Sci. 95 (6): 2452-66.
Roatt, B.M. et al. (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.
Front Immunol. 8: 217.
Karayannopoulou, M. et al. (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer.
Vet Immunol Immunopathol. 186: 45-50.
Lin, C.S. et al. (2018) Activating natural killer (NK) cytotoxicity of canine CD5-CD21- cells requires low surface CD5 density NK cells.
Iran J Vet Res. 19 (2): 87-95.
Graves, S.S. et al. (2019) Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody.
Vet Immunol Immunopathol. 211: 10-8.
Martini, V. et al. (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy.
Res Vet Sci. 125: 130-5.
Wolf-Ringwall, A. et al. (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol.
Vet Comp Oncol. 18 (3): 342-52.
Aguiar-Soares, R.D.O. et al. (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis.
Vaccines (Basel). 8 (4)Nov 17 [Epub ahead of print].
Sayag, D. et al. (2020) Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma.
Vet Clin Pathol. 49 (3): 476-83.
Lee, J. et al. (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
Biomed Res Int. 2021: 6690704.
Grudzien, M. et al. (2021) A newly established canine NK-type cell line and its cytotoxic properties.
Vet Comp Oncol. 19 (3): 567-77.
Lee, S.H. et al. (2021) Safety and immunological effects of recombinant canine IL-15 in dogs.
Cytokine. 148: 155599.
Karayannopoulou, M. et al. (2022) Effect of major versus minor mastectomy on host immunity in canine mammary cancer
Vet Immunol Immunopathol. 24 Feb: 110403.
Riccardo, F. et al. (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
J Immunother Cancer. 10 (5): e004007. [Epub ahead of print].
Jaensch, S. et al. (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia
Australian Veterinary Journal. [Epub ahead of print].
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"View all Anti-Dog Products
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up